- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Valiant Laboratories has announced a board meeting outcome that includes the approval of its audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2024. Key highlights include a standalone net loss of ₹609.05 lakh and consolidated net loss of ₹474.08 lakh during the period. The board also approved an increase in authorized share capital from ₹45 crore to ₹60 crore, subject to shareholder approval, and appointed Mr. Ashok Lakhamshi Chheda as a non-executive independent director for a five-year term. The resignation of Mr. Velji Karamshi Gogri, also an independent director, was acknowledged.
This development signals a strategic effort to strengthen governance and enhance capital structure, potentially positioning the company for future growth. While the financial outcomes reflect challenges, the new appointments may create a positive outlook for management effectiveness.